环极素作为治疗治疗脂质代谢障碍的治疗药物
Jiao Wu1, Jingyi Li1, Wenxiang Shao1
1Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
概括
环极素在治疗脂质代谢疾病,如尼曼-皮克型C,动脉样硬化和肥胖等方面表现有前途. 对糖尿病等疾病的机制和配方进行进一步的研究是有必要的.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 图书统计学 图书统计学
背景情况:
- 脂质代谢疾病对全球健康构成重大负担.
- 循环德克斯特林正在成为这些疾病的潜在治疗剂.
- 了解它们的疗效和机制对于临床应用至关重要.
研究的目的:
- 系统地比较环极在治疗脂质代谢疾病中的疗效和机制.
- 确定该领域的研究趋势和潜在的未来方向.
- 为随后的研究和临床应用提供洞察力.
主要方法:
- 在功能挖掘中使用了图书统计分析.
- 使用VOSviewer软件进行集群分析.
- 内容分析用于客观描述和对文献的准确分析.
主要成果:
- 超过50项研究组成了数据库,美国是著名的研究中心.
- 尼曼-皮克型C (NPC),动脉样硬化 (AS) 和肥胖症是密集研究的疾病,其中基-β-环素 (HP-β-CD) 是一个关键的环素类型.
- 研究涉及15种脂质代谢疾病,包括NPC,糖尿病和肥胖的临床试验,以及广泛的动物和细胞研究,探索与脂质代谢相关的机制.
结论:
- 环极素需要进一步研究其在各种脂质代谢疾病中的作用和机制.
- 在口服或注射配方中,循环德克斯的潜在疗效需要更多的研究,并代表着未来的研究重点.
- 这种文献计量分析强调了环氧在治疗脂质代谢障碍方面日益重要的重要性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
664
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
664
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
176
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
176
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204


